Previous 10 | Next 10 |
home / stock / gild / gild articles
Biogen Inc (NASDAQ:BIIB) released interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study. The Ph...
The Biden administration is working to preserve a crucial federal mandate compelling health insurers to cover preventive care services, including ...
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 4.93% on an annualized basis producing an average annual return...
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have hig...
Monday, Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share i...
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 ...
Gilead Sciences (NASDAQ:GILD) has announced an acquisition of CymaBay Therapeutics (NASDAQ:CBAY) that is expected to be completed in Q1 of 2024. Un...
Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share in cash or a to...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / July 1, 2024 / Jim Candler had a successful 40-year career in system operations before coming to Gilead three years ago to bring his tech expertise to the Human Resources team. "I was hired at 71 years old. What does that say about Gilead?" says Jim, Senior Direct...
2024-07-01 06:50:00 ET Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments. Three Motley Fool contributors think they've found magnificent stocks retir...
2024-06-24 13:00:04 ET Michael Yee from Jefferies issued a price target of $85.00 for GILD on 2024-06-24 10:57:00. The adjusted price target was set to $85.00. At the time of the announcement, GILD was trading at $71.24. The overall price target consensus is at $80.71 wi...